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Abstract
Background: Little is known about cost implications of anemia and its association with mortality
in chronic obstructive pulmonary disease (COPD). This claims analysis addresses these questions.
Methods: Using the the US Medicare claims database (1997–2001), this study identified Medicare
enrollees with an ICD-9 diagnosis of COPD. Concomitant anemia was identified based on ICD-9
codes or receipt of transfusions. Persons with anemia secondary to another disease state, a
nutritional deficiency or a hereditary disease were excluded. Medicare claims and payments,
resource utilization and mortality were compared between COPD patients with and without
anemia.
Results: Of the 132,424 enrollees with a COPD diagnosis, 21% (n = 27,932) had concomitant
anemia. At baseline, anemic patients were older, had more co-morbidities and higher rates of
health care resource use than non-anemic individuals with COPD. In a univariate analysis annual
Medicare payments for persons with anemia were more than double for those without anemia
($1,466 vs. $649, p < 0.001), the direction maintained in all categories of payments. Adjusting for
demographics, co-morbidities, and other markers of disease severity revealed that anemia was
independently associated with $3,582 incremental increase per patient (95% CI: $3,299 to $3,865)
in Medicare annual reimbursements. The mortality rate among COPD patients with anemia was
262 vs. 133 deaths per 1,000 person-years among those without anemia (p < 0.001).
Conclusion: Anemia was present in 21% of COPD patients. Although more prevalent in more
severely ill COPD patients, anemia significantly and independently contributes to the costs of care
for COPD and is associated with increased mortality.
Background
Chronic obstructive pulmonary disease (COPD) is a
major cause of both morbidity and mortality. In the
United States, more than 10 million adults suffer from
COPD and it is the fourth most common cause of death
[1]. Because of the continued high rate of smoking cou-
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pled with the aging of the population, analysts predict
that COPD will account for an increased proportion of
deaths in the near future [2]. With respect to morbidity,
COPD impairs both functional status and quality of life
[1]. Economically, the costs of COPD associated with
medical care and lost productivity are staggering, exceed-
ing $37 billion annually in the United States [3].
Anemia is commonly present among individuals with
chronic illnesses. In a broad range of medical conditions,
concomitant anemia is increasingly being recognized as a
risk factor associated with increased mortality [4,5]. There
is also growing evidence of increased health care utiliza-
tion and costs associated with anemia in disease states
such as chronic kidney disease, HIV, rheumatoid arthritis,
inflammatory bowel disease, congestive heart failure, and
cancer [6-8]. However, less is known regarding the impact
of anemia on mortality, morbidity, and costs of care for
patients with COPD. Cote and colleagues observed that
anemia was associated not only with increased mortality
but also with worsened dyspnea scores and functional
capacity as measured by the 6-minute walking distance in
a COPD cohort [9,10]. The effect of anemia was inde-
pendent of age, forced expiratory volume in one second,
and functional status. Similarly, a review of a French
national database indicated that subjects with severe oxy-
gen-dependent COPD and anemia experienced an
increased risk of hospitalization and short-term mortality
compared to those without anemia [11].
Despite the growing awareness of an association between
worse clinical and functional outcomes and anemia in
COPD patients, the financial implications of anemia in
COPD have not been examined previously. To determine
what incremental costs, if any, were associated with ane-
mia in COPD patients, and to confirm the association of
anemia with clinical and functional outcomes in a larger
population, data from Medicare beneficiaries in the
United States were analyzed.
Methods
Overview and database description
Medicare claims data for persons with COPD were ana-
lyzed; costs and outcomes for patients with anemia were
compared to those of patients without anemia. The data
source was the Medicare 5% beneficiary encrypted files
(BEF) from a recent five-year period (1997–2001), availa-
ble from the Centers for Medicare and Medicaid Services
(CMS). The BEF represents a systematic 5% sample of all
Medicare enrollees, which corresponds to essentially all
U.S. residents age 65 and older as well as select groups
younger than age 65 (e.g., patients with end-stage renal
disease or certain disabilities). This analysis included all
categories of the BEF data: Durable Medical Equipment
(DME), Inpatient Facility, Hospice, Outpatient Facility,
Home Health Agency (HHA), Skilled Nursing Facility
(SNF, nursing home), and Physician/Supplier (Part B)
claims.
Subjects and definitions
To be included in the cohort, beneficiaries had to have at
least two claims with diagnoses (primary or secondary) of
COPD from either Part B (physician/supplier) or outpa-
tient files. Persons under 65 years of age were excluded in
order to limit the impact of age as a source of heterogene-
ity in the study population. Those persons who were not
residents of either one of the 50 states or the District of
Columbia were also excluded. In addition, those with
known nutritional or hereditary anemias or with other
disease states that are commonly associated with anemia
(end stage renal disease, cancer, and gastrointestinal
bleeding) were eliminated. COPD patients with co-mor-
bid anemia were identified in two ways: claims with ICD-
9 codes specific for anemia, or receipt of blood transfu-
sions not associated with other apparent causes (e.g.,
acute blood loss from surgery, trauma, etc.). The appendix
lists the specific ICD-9 codes used to identify and define
the study cohort.
To control for variation in the utilization of medical care
services over time and the inherent inter-patient variabil-
ity in the need for healthcare encounters, an "index date"
was determined for each patient. For those with COPD
but without anemia, the date of the first medical claim
with a COPD diagnosis at least six months after entering
the database (at the time of either Medicare enrollment or
the start of the data set's availability) served as the index
date. For their anemic counterparts, the index date was the
first medical claim with a COPD diagnosis that was both
six months after that patient entered the data set and after
or concurrent with the claim for anemia. Only patients
with at least six months of Medicare enrollment prior to
their index date and at least 12 months of enrollment fol-
lowing their index date were included in the analysis.
Details regarding selection of case and control patients are
illustrated in Figure 1.
Outcome measures
Costs to the Medicare system for all medical care served as
the primary endpoint. To determine the attributable effect
of anemia, costs among persons with anemia and COPD
were compared to costs among non-anemic COPD
patients. Costs of care were stratified by the type of service
involved (e.g., durable medical equipment, inpatient
facility, hospice, etc.). Costs based on claims (submitted
charges) and actual payments (reimbursements) were
analyzed separately. All costs were inflated to 2004 U.S.
dollars by using the medical care component of the Con-
sumer Price Index.Cost Effectiveness and Resource Allocation 2006, 4:17 http://www.resource-allocation.com/content/4/1/17
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Rates of resource utilization represented a secondary end-
point. We evaluated the effect of anemia on the frequency
of the use of selected resources, including outpatient vis-
its, hospital admissions, ICU care, and home health
claims.
The association of anemia with survival in the study group
was also examined. Duration of survival was calculated
from index date to time of death and based on the
number of quarters of Medicare enrollment until the end
of either follow-up data on December 31, 2001, termina-
tion of Medicare entitlement, or death.
Co-variates of interest
In addition to the presence or absence of anemia, patient
demographics (e.g., age, gender, race/ethnicity) and the
distribution of other patient co-morbidities as categorized
by organ system using ICD-9 coding wee also assessed.
Although precise measures of COPD disease severity (e.g.,
pulmonary function test results) are not present in the
Medicare claims database, surrogate measures of disease
severity, including use of ventilation support, episodes of
serious pulmonary respiratory infections (chronic bron-
chitis and pneumonia), and numbers of hospitalizations
and emergency room visits for COPD in the six months
prior to the index date (as defined above) were utilized to
control for baseline disease severity in comparisons of
COPD patients with versus without anemia.
Statistics
Continuous data were analyzed with the Student's t-test or
the Mann-Whitney U test, as appropriate. Chi-square test
was used to compare categorical variables. All event rates
and frequencies were expressed as events per 1,000 per-
son-years or as annualized rates to allow for comparisons
between the two groups. Multivariate linear regression
modeling was used to calculate the independent costs of
care associated with anemia in COPD. Regressions
included demographic variables and the disease severity
surrogate measures noted above and identified a priori as
biologically important confounders that would affect
resource use in COPD. To determine survival, total per-
son-years of follow up, total deaths, and death rates (per
1,000 person-years) were calculated using the Kaplan-
Meier method. For this survival analysis, surviving enroll-
ees were censored at December 31, 2001 (the end of the
data capture period) or at the end of their Medicare enroll-
ment if before that date. Survival curves were compared
with the log-rank test. P values of <0.05 were assumed to
represent statistical significance, and 95% confidence
intervals are reported where appropriate. All analyses were
conducted using SAS version 9.1 (SAS Institute, Cary,
NC).
Results
The cohort included 132,424 patients with COPD.
Approximately 21% (n = 27,932) were identified as hav-
ing concomitant anemia that was not associated with
nutritional or hereditary anemias, acute blood loss, end-
stage renal disease, or malignancy. As shown in Table 1,
anemic patients tended to be older and were more likely
to be female. In the quarter prior to the index date, anemic
patients were 1.71 times (95% CI: 1.63–1.79) more likely
to have needed mechanical ventilation than non-anemic
patients. With respect to comorbid conditions (Table 1),
neurologic, respiratory, and musculoskeletal diagnoses
were more frequent in those without anemia. Skin and GI
conditions were similar between the two groups, and all
other conditions occurred more often in the anemic pop-
ulation.
Anemia Among COPD Patients: Case and Control Identification Figure 1
Anemia Among COPD Patients: Case and Control Identification.Cost Effectiveness and Resource Allocation 2006, 4:17 http://www.resource-allocation.com/content/4/1/17
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Specific rates of health care utilization during the six
months prior to the index date (i.e., prior to identification
of these patients having anemia) were greater for patients
with co-morbid anemia (Table 2). During the six-month
baseline period, anemic persons had significantly more
claims for hospitalizations, ICU care, and episodes of
acute exacerbations of COPD (AECB) and pneumonia.
For example, being classified with co-morbid anemia was
associated with a greater need for ICU care (15.5 claims
per 100 patients with anemia during the baseline period
vs. 7.3 claims per 100 patients without anemia, p <
0.001). These differences indicate greater baseline severity
of illness among patients with COPD and anemia.
Table 3 presents the unadjusted total claims (charges) and
reimbursements (payments) after the index date (in 2004
dollars). Average annual payments from Medicare were
substantially higher among those with anemia. Medicare
spent $1,466 per patient per year among COPD patients
with anemia vs. $649 per patient per year in non-anemic
COPD patients (p < 0.001). Resource utilization rates
among patients with anemia (Table 4.), as well as pay-
ments for COPD patients with anemia were higher in
every resource utilization category (Figure 2). Rates of
mechanical ventilation, ICU care, emergency department
visits, and other resource use were also higher among
COPD patients diagnosed with anemia (Table 4).
Costs for Medicare enrollees in both groups, with and
without anemia, rose after the index date. The increase in
claims was 78.1% for COPD patients with anemia and
50.9% for patients without anemia (p < 0.001); the
increase in payments was 71.5% for patients with anemia
and 48.5% among patients without anemia (p < 0.001).
Using linear regression to control for baseline differences
in severity of illness (e.g., number of co-morbid illnesses,
need for ventilation support, and episodes of pneumonia
and acute exacerbations of chronic bronchitis in the six
months prior to the index date) and preceding health care
use (e.g., frequency of hospital admissions and emergency
room care for COPD) the incremental independent
annual per patient charges and reimbursements associ-
ated with anemia among COPD patients were calculated
to be $8,811 (p < 0.001, 95% CI: $8,136 to $9,487) for
charges and $3,582 (p < 0.001, 95% CI: $3,299 to $3,865)
for payments. The independent contribution of anemia to
costs in COPD was present in all categories of resource uti-
lization (Figure 3). Of note, anemia care (defined as med-
ical claims with an anemia diagnosis) did not appear to
account directly for these incremental differences in cost.
Table 1: Baseline Patient Characteristics
Variable COPD with Anemia
(n = 27,932)
Non-anemic COPD
(n = 104,492)
P value
Demographics
Age, mean (SD), years 77.5 ± 7.8 74.7 ± 7.6 <0.001
Age distribution (years, %)
65–69 19.0% 31.5% <0.001
70–74 20.1% 23.0%
75–79 21.4% 18.7%
80–84 18.7% 13.7%
> 84 20.6% 12.1%
Male (%) 34.2% 42.4% <0.001
Pulmonary Characteristics of Interest Present in the Six Month Baseline Period
Concomitant asthma diagnosis 25.2% 22.6% <0.001
Use of supplemental oxygen 9.8% 3.7% <0.001
Comorbidities, % (by ICD-9 coded organ system) Present in the Six Month Baseline Period
Infectious and parasitic 1.7% 1.4% <0.001
Skin disorders 2.3% 2.2% NS
Digestive disorders 2.5% 2.5% NS
Mental disorders 3.3% 2.9% <0.001
Genitourinary disorders 3.9% 3.3% <0.001
Blood diseases 4.3% 0.8% <0.01
Nervous system 4.4% 6.3% <0.001
Musculoskeletal disorders 7.7% 9.0% <0.001
Other respiratory disorders 8.3% 8.8% <0.001
Endocrine and metabolic 8.5% 7.9% <0.001
Circulatory disorders 26.8% 26.0% <0.01
Abbreviations: COPD – Chronic obstructive pulmonary disease, NS – not significantCost Effectiveness and Resource Allocation 2006, 4:17 http://www.resource-allocation.com/content/4/1/17
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Less than 1% of the over 890,000 claims for the co-mor-
bid anemia population filed in the 12 months after the
index date had a diagnosis code specific for anemia.
Persons with anemia complicating their COPD had a
nearly two-fold increase in death rates (262 per 1,000 per-
son-years of follow-up) compared to the non-anemic
individuals (133 deaths per 1,000 person-years of follow-
up, p < 0.001). The association of anemia and mortality
was stronger among younger Medicare patients; among
those 65–69 years of age, anemia was associated with an
odds ratio for death of 2.07 (95% CI: 1.94 to 2.22). In
contrast, among the 80–84 year old cohort the odds ratio
for mortality in those with anemia and COPD was 1.42
(95% CI: 1.36 to 1.49).
Discussion
This analysis of the Medicare population indicates that
anemia is frequent in COPD, occurring in 21% of the cur-
rent study patients. More importantly, the presence of
anemia is associated with substantial economic burden
and increased resource utilization among these benefici-
aries. Although persons with COPD and anemia are more
severely ill than their non-anemic counterparts, the asso-
ciation of anemia and costs is independent of multiple
important potential confounders. Moreover, the majority
of incremental costs among anemic COPD patients is not
coded as direct care for anemia. In addition, co-morbid
anemia is associated with increased mortality for COPD
patients.
Table 3: Total Medicare Claims (Charges) and Reimbursements (Payments) for COPD Patients with versus without Anemia After 
Index Date
COPD with Anemia (n = 27,932) Non-anemic COPD (n = 104,492)
Type of 
Resource 
Utilization
Total 
Number of 
Claims
Total Claim 
Amount
Average 
Claim per 12 
M Enrollment
Average 
Payment per 
12 M 
Enrollment
Total 
Number of 
Claims
Total Claim 
Amount
Average 
Claim per 12 
M Enrollment
Average 
Payment per 
12 M 
Enrollment
DME 200,952 $78,660,190 $162 $71 693,549 $262,757,934 $101 $44
HHA 34,113 $59,075,953 $121 $96 83,185 $129,983,681 $50 $39
Hospice 5,182 $13,823,214 $28 $27 13,204 $35,768,474 $14 $13
Inpatient 43,129 $965,219,860 $1,985 $788 107,793 $2,061,627,072 $789 $342
Outpatient 181,577 $110,476,975 $227 $62 700,001 $375,269,221 $144 $36
Part B 1,347,897 $324,691,886 $668 $254 3,781,373 $878,749,293 $336 $121
SNF 18,907 $153,345,595 $315 $168 34,515 $280,467,242 $107 $54
Total* 1,831,757 $1,705,293,673 $3,506 $1,466 5,413,620 $4,024,622,917 $1,541 $649
*Claims and payments significantly different between patients with and without anemia, p < 0.001 Note: 1997–2001 data inflation-adjusted to 2004 
$ using the Medical Consumer Price Index
Abbreviations: 12 M – 12 months of continuous Medicare enrollment, DME – durable medical equipment, HHA – home health assistance, SNF – 
skilled nursing facility
Table 2: Baseline Resource Utilization
Characteristic COPD with Anemia 
(n = 27,932)
Non-anemic COPD 
(n = 104,492)
P value
# of hospitalizations in 6 months before index date
Claims per 100 patients 63.2 29.7 <0.001
Claims per 12 month period 1.26 0.59 <0.001
# of ICU encounters in 6 months before index date
Claims per 100 patients 15.5 7.3 <0.001
Claims per 12 month period 0.31 0.15 <0.001
# of AECB medical encounters in 6 months before index date
Claims per 100 patients 27.0 16.0 <0.001
Claims per 12 month period 0.54 0.32 <0.001
# of pneumonia medical encounters in 6 months before index date
Claims per 100 patients 83.5 34.9 <0.001
Claims per 12 month period 1.67 0.79 <0.001
Abbreviations: AECB – acute exacerbations of chronic bronchitis, COPD – chronic obstructive pulmonary disease, ICU – intensive care unitCost Effectiveness and Resource Allocation 2006, 4:17 http://www.resource-allocation.com/content/4/1/17
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Prior research into anemia in COPD is limited. John and
colleagues examined a population of 101 COPD patients
and estimated the prevalence of anemia at 13% [12]. They
noted that neither age nor spirometric measures differed
between anemic and non-anemic persons. Those with
lower hemoglobins, however, had more extensive sys-
temic inflammation as measured by both IL-6 and C-reac-
tive protein levels [12]. The variability in the prevalence of
anemia between theirs and the current study likely reflects
differences in definitions. John et al. relied on actual
hemoglobin measurements while the current administra-
tive data are limited to ICD-9 codes. Additionally, the
mean age in their analysis was approximately 61 years; the
present study's cohort was older since it derived from a
Medicare sample, and the prevalence of anemia is known
to increase with increasing age [13]. Somewhat contrary to
Adjusted Incremental Difference in Medicare Payments for  COPD by Category Figure 3
Adjusted Incremental Difference in Medicare Payments for 
COPD by Category. Abbreviations: DME – durable medical 
equipment, HHA – home health assistance, SNF – skilled 
nursing facility.
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Table 4: Resource Utilization After Index Date
COPD with 
Anemia
(n = 27,932)
Non-anemic COPD 
(n = 104,492)
P value
Type of Resource 
Utilization
Total Number* Annual Rate Total Number*A n n u a l  R a t e
Outpatient Visits 151,930 3.76 678,416 3.12 <0.001
Emergency 
Department Visits
19,878 0.49 74,951 0.34 0.038
Hospitalizations 36,970 0.91 106,230 0.49 0.036
ICU Admissions 9,062 0.22 25,469 0.12 <0.001
Ventilation 
Episodes
2,270 0.06 6,188 0.03 <0.001
Home Health Care 
Visits
1,374 0.03 4,302 0.02 <0.001
Nursing Home 
Admissions
4,342 0.11 10,298 0.05 <0.001
Medication 
Prescriptions (non-
self-administered)
26,689 0.66 89,361 0.41 0.334
Transfusions 6,348 0.16 6,394 0.03 <0.001
*From Index Date to end of data, end of 12 month study period, or end of Medicare enrollment
Abbreviations: COPD – Chronic obstructive pulmonary disease, ICU – intensive care unit
The Impact of Anemia on Annual Medicare Payments for  COPD Patients by Category Figure 2
The Impact of Anemia on Annual Medicare Payments for 
COPD Patients by Category. Abbreviations: DME – durable 
medical equipment, HHA – home health assistance, SNF – 
skilled nursing facility.
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the findings by John, a recent study by Chambellan and
coworkers in a cohort of COPD patients with severe oxy-
gen-dependent COPD demonstrated that anemia
(defined by laboratory values according to the WHO cri-
teria [14]), present in 8.2–12.6%, was in fact correlated
with age and disease severity in this population, and, con-
sistent with the current findings, hematocrit was an inde-
pendent predictor of survival, hospital admission rate and
duration of hospitalization [11]. Cote and co-workers,
focusing on a population from a US Veterans Affairs pul-
monary clinic, estimated the prevalence of anemia at 30%
[9]. As in the John et al. study, these investigators had
patient level hemoglobin data available. Similar to the
present findings, Cote et al. reported that anemic COPD
patients had more co-morbid illnesses [9,10]. They also
concluded that the presence of anemia independently cor-
related with mortality [9,10].
While it is likely that CKD, advanced age or certain medi-
cation exposure may play a role in the development of
anemia in this population, at least one study points to the
possible role of inflammation and resistance to elevated
levels of erythropoietin [12]. Etiology notwithstanding,
our study suggests anemia is highly prevalent in the
COPD population and associated with worse clinical and
economic outcomes.
The present study builds on prior data and suggests that
anemia is common in COPD. As it was necessary in the
present study to use ICD-9 codes rather than hemoglobin
values, these findings likely underestimate the frequency
of anemia. Examining a very large sample, however, adds
to the robustness of the conclusions. Furthermore, this
study was able to control for many confounders that the
earlier reports could not assess. Specifically, the current
analysis accounted for prior health care utilization and
factors associated with COPD severity, such as the fre-
quency of episodes of AECB and pneumonia. This study is
also unique in that it measures the economic impact of
anemia in COPD and describes the increased utilization
of various healthcare resources among patients with ane-
mia. Finally, this study was also able to corroborate previ-
ous work indicating that COPD patients with anemia are
at higher risk for death.
The association between anemia and increased risk of
mortality seen here among COPD patients parallels previ-
ous reports of links between anemia and decreased sur-
vival in other disease states. For example, in subjects with
left ventricular dysfunction, anemia independently
adversely affects survival [15,16]. Similarly, in chronic
kidney disease, anemia not only affects quality of life but
also worsens survival [17]. This study's finding of rela-
tively high costs of medical care for individuals with
COPD (even those who do not have anemia) is not sur-
prising, given that both increased age and decreased
health status are associate with increased costs in several
different components of healthcare [18]. Specifically, in
COPD, direct healthcare costs in the United States were
estimated to exceed $18 billion in 2002 and COPD led to
nearly 750,000 hospital admissions [19]. These hospitali-
zations, along with treatment of AECB, are major drivers
of costs. Results of this study, indicating that inpatient
care was the single largest category of Medicare claims for
this population, support findings from previous studies.
This study has several important limitations. First, as a ret-
rospective study, it is exposed to various forms of bias.
Second, since the data source was administrative claims
data, findings may have been affected by coding bias; that
is, only those COPD patients and the subset with anemia
who had Medicare claims with appropriate ICD-9 diagno-
sis codes could be identified, though the presence of such
codes could not guarantee the appropriateness of these
diagnoses. The large sample size, however, balances these
concerns, and for some endpoints, such as mortality and
hospitalizations, the results are in accordance with other
studies. Further, prior large chart audits indicate that ICD-
9 codes for COPD are actually both specific and sensitive
for this condition [20]. Third, as mentioned earlier, ane-
mia was defined based on ICD-9 coding. As a majority of
US pulmonologists participating in a recent survey did
not classify anemia as being present among COPD
patients using a threshold hemoglobin value of 12 g/dL, it
is unlikely that this study overestimated the true preva-
lence of anemia in this population and may well have
underestimated it [21]. If clinicians do not believe anemia
is present, they are unlikely to use an anemia diagnosis
code for the provided services. Additionally, there is no
reason to believe, a priori, that bias in recording anemia
would lead to the more "expensive" patients consistently
being labeled as anemic. Finally, no specific measures of
disease severity were available. Hence surrogate markers
of severity of illness, which correlate with outcomes and
have been validated in previous health services research in
COPD, were utilized. Moreover, other than the recently
proposed BODE index, no global, validated severity score
in COPD exists [22]. Despite these best efforts at adjusting
for identifiable confounders, residual confounding can-
not be excluded as a potential source of the independent
relationship between anemia and worsened outcomes
shown in this study.
In conclusion, anemia is a comorbidity commonly associ-
ated with COPD. Although the nature of this retrospective
observational study precludes any inference of causality, it
is clear that anemia in this patient population is associ-
ated with increased healthcare costs and resource utiliza-
tion, as well as worsened survival. Future research is
warranted to define more accurately the epidemiologyPublish with BioMed Central    and   every 
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and the etiology of anemia in COPD, to evaluate the
impact of anemia on quality of life among persons with
COPD, and to explore options for and effects of treating
anemia in COPD.
Appendix
Codes used to identify study population
• COPD Patients: ICD9 491–492, 496
• Presence of Anemia: ICD9 280–281, 283–285, or blood
transfusion w/o major surgery or trauma (blood pint>0
but DRG # 1–8, 27–30, 36–42, 49–63, 72, 75–77,83–84,
104–120, 146–171, 191–201, 209–236, 257–270, 280–
282, 285–293, 302–315, 334–345, 353–365, 370–394,
400–410, 413–418, 424, 439–455, 468–511)
Exclude ESRD (Medicare Status Code = 10 aged w/o ESRD
or ICD9 996.68, 996.73, V45.1, V56), malignancies
(ICD9 140–239), HIV (ICD9 042, 079.53), GI bleeding
(ICD9 456.0, 456.20, 530.21, 530.7)
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